Vinva Investment Management Ltd Grows Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Vinva Investment Management increased its stake in Zimmer Biomet (ZBH) by 785.1% in Q3 to 110,759 shares, worth $10.885 million (about 0.06% of the company).
• Zimmer Biomet beat quarterly EPS estimates ($2.42 vs. $2.38) and revenue ($2.24B), posted 10.9% year-over-year revenue growth, and set FY2026 EPS guidance of 8.300–8.450.
• The company declared a quarterly dividend of $0.24 (annualized $0.96) for a ~1.0% yield, while analysts' consensus is a "Hold" rating with an average target price of $106.20.

Vinva Investment Management Ltd grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 785.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,759 shares of the medical equipment provider's stock after purchasing an additional 98,245 shares during the period. Vinva Investment Management Ltd owned 0.06% of Zimmer Biomet worth $10,885,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Brighton Jones LLC purchased a new position in shares of Zimmer Biomet during the 4th quarter worth about $204,000. Sivia Capital Partners LLC purchased a new stake in Zimmer Biomet in the second quarter valued at approximately $232,000. United Bank grew its holdings in Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock valued at $1,085,000 after purchasing an additional 1,153 shares during the period. Atlantic Union Bankshares Corp acquired a new position in Zimmer Biomet during the second quarter worth approximately $80,000. Finally, Resona Asset Management Co. Ltd. raised its stake in Zimmer Biomet by 5.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider's stock worth $6,197,000 after purchasing an additional 3,634 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ZBH shares. Wall Street Zen lowered shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. TD Cowen upgraded Zimmer Biomet from a "hold" rating to a "buy" rating in a report on Monday, January 26th. The Goldman Sachs Group lowered Zimmer Biomet from a "neutral" rating to a "sell" rating and set a $93.00 target price on the stock. in a research report on Friday, January 9th. UBS Group reiterated a "sell" rating and issued a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. Finally, Robert W. Baird restated a "neutral" rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $106.20.

Zimmer Biomet Stock Up 0.7%

Shares of Zimmer Biomet stock opened at $94.08 on Monday. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The stock has a market cap of $18.41 billion, a price-to-earnings ratio of 26.58, a price-to-earnings-growth ratio of 1.92 and a beta of 0.58. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The company has a fifty day moving average price of $92.13 and a 200 day moving average price of $95.60.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same period last year, the company posted $2.31 earnings per share. The firm's revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet's dividend payout ratio is currently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.